Back to results
US 2025/0144117 A1Published application
Iloprost compositions and formulations thereof
AssigneeBTG International Limited
InventorsWade W. BENTON, Kevin A. CHRISTAL
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to treatment of systemic sclerosis with symptomatic Raynaud's Phenomenon by intravenous or subcutaneous administration of iloprost or a pharmaceutically acceptable salt thereof.
Claims17
1-43. (canceled)
A pharmaceutical composition, comprising:
- i. about 0.1 mg/mL of iloprost, or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, relative to a total volume of the composition;
- ii. about 0.24 mg/mL of tromethamine, relative to a total volume of the composition;
- iii. sodium chloride;
- and
- iv. ethanol.
2 more elements
A pharmaceutical composition, comprising:
- i. about 0.1 mg/mL of iloprost, or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, relative to a total volume of the composition;
- ii. about 0.24 mg/mL of tromethamine, relative to a total volume of the composition;
- iii. about 9.0 mg/mL of sodium chloride, relative to a total volume of the composition;
- and
- iv. ethanol.
2 more elements
A pharmaceutical composition, comprising:
- i about 0.1 mg/mL of iloprost, or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, relative to a total volume of the composition;
- ii. about 0.24 mg/mL of tromethamine, relative to a total volume of the composition;
- iii. about 9.0 mg/mL of sodium chloride, relative to a total volume of the composition;
- and
- iv. ethanol;
- wherein the composition has a pH of about 8 to about 9.
3 more elements
Dependencies are inferred from the claim text.